Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Cash & Equivalents (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Cash & Equivalents for 11 consecutive years, with $16.1 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 16.28% to $16.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.1 million through Dec 2025, down 16.28% year-over-year, with the annual reading at $16.1 million for FY2025, 16.28% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $16.1 million at Marker Therapeutics, down from $17.6 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $64.5 million in Q1 2021, with the low at $6.4 million in Q1 2023.
  • Average Cash & Equivalents over 5 years is $23.0 million, with a median of $17.5 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents surged 98.34% in 2021, then tumbled 77.65% in 2023.
  • Over 5 years, Cash & Equivalents stood at $42.4 million in 2021, then plummeted by 72.18% to $11.8 million in 2022, then increased by 28.26% to $15.1 million in 2023, then rose by 27.01% to $19.2 million in 2024, then decreased by 16.28% to $16.1 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $16.1 million, $17.6 million, and $10.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.